JP2015520146A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520146A5 JP2015520146A5 JP2015510925A JP2015510925A JP2015520146A5 JP 2015520146 A5 JP2015520146 A5 JP 2015520146A5 JP 2015510925 A JP2015510925 A JP 2015510925A JP 2015510925 A JP2015510925 A JP 2015510925A JP 2015520146 A5 JP2015520146 A5 JP 2015520146A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- alkyl
- compound
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 25
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- -1 6-methylheptan-2-yl Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical group 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 125000003367 polycyclic group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims 2
- OYXZMSRRJOYLLO-UHFFFAOYSA-N 7alpha-Hydroxycholesterol Natural products OC1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 OYXZMSRRJOYLLO-UHFFFAOYSA-N 0.000 claims 2
- OYXZMSRRJOYLLO-KGZHIOMZSA-N 7beta-hydroxycholesterol Chemical compound C([C@@H]1O)=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 OYXZMSRRJOYLLO-KGZHIOMZSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 125000000468 ketone group Chemical group 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 1
- SIJBDWPVNAYVGY-UHFFFAOYSA-N 2,2-dimethyl-1,3-dioxolane Chemical compound CC1(C)OCCO1 SIJBDWPVNAYVGY-UHFFFAOYSA-N 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000001980 alanyl group Chemical group 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 1
- 210000001130 astrocyte Anatomy 0.000 claims 1
- 239000003833 bile salt Substances 0.000 claims 1
- 229940093761 bile salts Drugs 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000006196 drop Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000002073 methionyl group Chemical group 0.000 claims 1
- MCLPGRDSFRGNHK-UHFFFAOYSA-N phenanthren-3-yl 2,2-dimethyl-1,3-dioxolane-4-carboxylate Chemical compound CC1(OCC(O1)C(=O)OC=1C=CC=2C=CC3=CC=CC=C3C=2C=1)C MCLPGRDSFRGNHK-UHFFFAOYSA-N 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000011450 sequencing therapy Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305518.8A EP2662382B1 (fr) | 2012-05-10 | 2012-05-10 | Dérivés de stérol, leur procédé de préparation, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement du glioblastome multiple |
| EP12305518.8 | 2012-05-10 | ||
| US201261656151P | 2012-06-06 | 2012-06-06 | |
| US61/656,151 | 2012-06-06 | ||
| PCT/IB2013/053669 WO2013168096A1 (en) | 2012-05-10 | 2013-05-07 | Sterol derivatives and use thereof for treating diseases involving transformed astrocyte cells or for treating malignant haemopathies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015520146A JP2015520146A (ja) | 2015-07-16 |
| JP2015520146A5 true JP2015520146A5 (enExample) | 2016-06-30 |
| JP6270823B2 JP6270823B2 (ja) | 2018-01-31 |
Family
ID=46149353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510925A Active JP6270823B2 (ja) | 2012-05-10 | 2013-05-07 | ステロール誘導体、及び形質転換した星状膠細胞に関係する疾患を治療するため、または悪性血液疾患を治療するためのその使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10800806B2 (enExample) |
| EP (2) | EP2662382B1 (enExample) |
| JP (1) | JP6270823B2 (enExample) |
| KR (1) | KR102160316B1 (enExample) |
| CN (1) | CN104302655B (enExample) |
| BR (1) | BR112014026948B1 (enExample) |
| CA (1) | CA2871714C (enExample) |
| CY (2) | CY1117723T1 (enExample) |
| DK (2) | DK2662382T3 (enExample) |
| ES (2) | ES2580331T3 (enExample) |
| HR (2) | HRP20180345T1 (enExample) |
| HU (2) | HUE029243T2 (enExample) |
| IN (1) | IN2014DN09437A (enExample) |
| LT (1) | LT2847204T (enExample) |
| ME (1) | ME02436B (enExample) |
| PL (2) | PL2662382T3 (enExample) |
| PT (2) | PT2662382T (enExample) |
| RS (2) | RS54926B1 (enExample) |
| RU (1) | RU2627710C2 (enExample) |
| SI (2) | SI2662382T1 (enExample) |
| SM (2) | SMT201800147T1 (enExample) |
| TR (1) | TR201802700T4 (enExample) |
| WO (1) | WO2013168096A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3013048A1 (fr) * | 2013-11-12 | 2015-05-15 | Beta Innov | Derive de sterol, son procede de preparation, composition pharmaceutique le contenant et son utilisation pour le traitement du glioblastome multiforme |
| EP3593789A1 (fr) * | 2018-07-11 | 2020-01-15 | Beta Innov | Composition contenant un dérivé de 7beta-hydroxycholestérol et un véhicule lipidique, et son utilisation dans le traitement de pathologies néoplasiques |
| KR102748745B1 (ko) * | 2021-05-18 | 2025-01-03 | 연세대학교 산학협력단 | 암의 예방, 개선 또는 치료용 조성물 |
| KR102689231B1 (ko) * | 2021-05-18 | 2024-07-30 | 연세대학교 산학협력단 | 암의 예방, 개선 또는 치료용 조성물 |
| WO2024030660A2 (en) * | 2022-08-04 | 2024-02-08 | University Of Massachusetts | Cholesterol-modified hyaluronic acids |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9602100D0 (sv) * | 1996-05-30 | 1996-05-30 | Magnus Axelson | New pharmaceuticals |
| RU2005112247A (ru) * | 2002-09-25 | 2006-01-20 | Форбз Меди-Тек Инк. (Ca) | Новые структуры и композиции, содержащие стеролы и/или станолы и определенные классы противовоспалительных средств, и их применение для лечения или предупреждения сердечно-сосудистого заболевания, лежащих в его основе состояний, включая гиперлипидемию, и других нарушений, при которых воспаление является частью их этиологии или проявления |
-
2012
- 2012-05-10 RS RS20160499A patent/RS54926B1/sr unknown
- 2012-05-10 SI SI201230585A patent/SI2662382T1/sl unknown
- 2012-05-10 DK DK12305518.8T patent/DK2662382T3/en active
- 2012-05-10 ME MEP-2016-134A patent/ME02436B/me unknown
- 2012-05-10 HU HUE12305518A patent/HUE029243T2/en unknown
- 2012-05-10 EP EP12305518.8A patent/EP2662382B1/fr active Active
- 2012-05-10 PL PL12305518.8T patent/PL2662382T3/pl unknown
- 2012-05-10 PT PT123055188T patent/PT2662382T/pt unknown
- 2012-05-10 ES ES12305518.8T patent/ES2580331T3/es active Active
-
2013
- 2013-05-07 JP JP2015510925A patent/JP6270823B2/ja active Active
- 2013-05-07 PT PT137294708T patent/PT2847204T/pt unknown
- 2013-05-07 HR HRP20180345TT patent/HRP20180345T1/hr unknown
- 2013-05-07 KR KR1020147034290A patent/KR102160316B1/ko active Active
- 2013-05-07 LT LTEP13729470.8T patent/LT2847204T/lt unknown
- 2013-05-07 SI SI201330962T patent/SI2847204T1/en unknown
- 2013-05-07 WO PCT/IB2013/053669 patent/WO2013168096A1/en not_active Ceased
- 2013-05-07 CA CA2871714A patent/CA2871714C/en active Active
- 2013-05-07 DK DK13729470.8T patent/DK2847204T3/en active
- 2013-05-07 CN CN201380023824.4A patent/CN104302655B/zh active Active
- 2013-05-07 RS RS20180237A patent/RS57065B1/sr unknown
- 2013-05-07 EP EP13729470.8A patent/EP2847204B1/en active Active
- 2013-05-07 RU RU2014149705A patent/RU2627710C2/ru active
- 2013-05-07 PL PL13729470T patent/PL2847204T3/pl unknown
- 2013-05-07 SM SM20180147T patent/SMT201800147T1/it unknown
- 2013-05-07 BR BR112014026948-3A patent/BR112014026948B1/pt active IP Right Grant
- 2013-05-07 ES ES13729470.8T patent/ES2662123T3/es active Active
- 2013-05-07 IN IN9437DEN2014 patent/IN2014DN09437A/en unknown
- 2013-05-07 TR TR2018/02700T patent/TR201802700T4/tr unknown
- 2013-05-07 US US14/399,336 patent/US10800806B2/en active Active
- 2013-05-07 HU HUE13729470A patent/HUE037004T2/hu unknown
-
2016
- 2016-06-07 HR HRP20160624TT patent/HRP20160624T1/hr unknown
- 2016-07-05 SM SM201600215T patent/SMT201600215B/it unknown
- 2016-07-05 CY CY20161100621T patent/CY1117723T1/el unknown
-
2018
- 2018-03-13 CY CY20181100306T patent/CY1120395T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6833844B2 (ja) | アルギナーゼ活性を阻害する組成物及び方法 | |
| JP6480025B2 (ja) | イオン性化合物及び組成物並びにその使用 | |
| EP3229810B1 (en) | Phospholipid ether analogs as cancer-targeting drug vehicles | |
| CA2669913C (en) | Endoxifen methods and compositions | |
| JP2015520146A5 (enExample) | ||
| TW202308658A (zh) | 異喹啉穩定之脂質奈米粒子調配物 | |
| EP2672974A1 (en) | Hybrid opioid compounds and compositions | |
| WO2014138425A1 (en) | Cyclosporine a-steroid conjugates | |
| AU2007328007A1 (en) | Prodrugs and methods of making and using the same | |
| CN109311809A (zh) | 阳离子脂质 | |
| JP2008508357A5 (enExample) | ||
| JP5011113B2 (ja) | 抗癌剤 | |
| RU2014149705A (ru) | Производные стеринов и их применение для лечения заболеваний, связанных с трансформированными астроцитными клетками, или для лечения злокачественных заболеваний крови | |
| JP2025087716A (ja) | 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート | |
| JP2013525290A5 (enExample) | ||
| TWI837128B (zh) | 萘普生(ｎａｐｒｏｘｅｎ)及普加巴林(ｐｒｅｇａｂａｌｉｎ)之1-(醯氧基)-烷基胺甲酸酯之藥物結合物的結晶型 | |
| JP7630193B2 (ja) | １，２，４，５－テトラオキサン化合物の標的化送達及びその使用 | |
| EP3286198B1 (en) | Compounds for treating pruritic conditions | |
| RU2799809C2 (ru) | Кристаллические формы 1-(ацилокси)-алкилкарбаматных конъюгатов лекарственных средств напроксена и прегабалина | |
| CN116887825A (zh) | 含有格隆铵·水杨酸盐的药物 | |
| BR112020022885B1 (pt) | Processo para preparar um composto e composto | |
| KR20230114274A (ko) | 5α-하이드록시-6β-[2-(1H-이미다졸-4-일)에틸아미노]콜레스탄-3β-올의전구약물 및 암 치료에 사용하기 위한 이를 포함하는 약제학적 조성물 | |
| WO2008022128A2 (en) | Transdermal delivery of meptazinol | |
| JP2003081819A (ja) | 抗癌活性を有するフィトスフィンゴシン誘導体 | |
| HK1136198B (en) | Endoxifen for use in the treatment of cancer |